Tunis Med. 2025 Feb 5;103(2):217-224. doi: 10.62438/tunismed.v103i2.5318.
ABSTRACT
INTRODUCTION: There are no clear data on the incidence and predictors of arterial and venous thromboembolic (TE) events in COVID-19 ambulatory patients.
AIM: We conducted this study to analyze thromboembolic complications in this setting and to compare the efficacy and safety of Rivaroxaban to LMWHs as a thromboprophylaxis treatment.
METHODS: This is an observational study including COVID-19 patients treated on an outpatient basis. We analysed the predictors of thromboembolic events.
RESULTS: We included 2089 patients with COVID19 managed on an outpatient basis during the period from October 01, 2020 to December 31, 2021. The mean age of our patients was 43±16 years. The incidence of venous and arterial TE complications was 0.9%. Predictive factors for arteriovenous thromboembolic complications were hormonal contraception (OR=23), moderate clinical form (OR=3.5), recent surgery or miscarriage in the month preceding COVID-19 (OR=9.2) and CT signs of COVID-19 (OR=4.9). In contrast, physical activity proved to be a protective factor. Thromboprophylaxis was prescribed in 22.5% of cases: LMWH in 18.1%, Rivaroxaban in 3.7% and a combination of the two molecules successively in 0.6% of patients. There was no statistical difference in thromboembolic or major bleeding complications between the Rivaroxaban and LMWH groups.
CONCLUSION: Our study showed that the incidence of thromboembolic complications is very low in Covid-19 ambulatory patients.
PMID:40096722 | DOI:10.62438/tunismed.v103i2.5318